Literature DB >> 27317360

Theory of mind and executive functions in schizophrenia and bipolar disorder: A cross-diagnostic latent class analysis for identification of neuropsychological subtypes.

Emre Bora1, Baybars Veznedaroğlu1, Simavi Vahip1.   

Abstract

OBJECTIVE: Executive dysfunction is a common feature of schizophrenia and bipolar disorder (BP). While deficits in social cognitive abilities, including theory of mind (ToM), have been suggested to be specific to schizophrenia, available evidence suggests that there is also a significant overlap in social cognitive performances of both disorders. However, there is significant heterogeneity of executive dysfunction and ToM deficits in BP and schizophrenia. Cross-diagnostic data-driven methods can reveal potential neurocognitive subtypes characterized by relatively selective deficits in social cognition.
METHODS: Neurocognitive subgroups were investigated using latent class analysis, based on executive functions and ToM, in a mixed sample of 97 clinically stable patients with schizophrenia or BP and 27 healthy controls.
RESULTS: Four neurocognitive subgroups, including a "neuropsychologically normal" cluster, a severe global impairment cluster and two clusters of mixed cognitive profiles were found. Severe impairment cluster was characterized by particularly severe ToM deficits and predominantly included patients with schizophrenia. Schizophrenia patients in this cluster had severe negative symptoms. In contrast, individuals with BP compared to schizophrenia patients were more likely to be included in the "neuropsychologically normal" cluster.
CONCLUSION: Identification of distinctive neurobiological subtypes of patients based on social and non-social cognitive profiles can improve classification of major psychoses. Neurocognitive subgroupings of patients might be also beneficial for intervention strategies including cognitive rehabilitation.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bipolar disorder: cognition: heterogeneity; Executive functions; Schizophrenia; Theory of mind

Mesh:

Year:  2016        PMID: 27317360     DOI: 10.1016/j.schres.2016.06.007

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  11 in total

1.  A symptom-based continuum of psychosis explains cognitive and real-world functional deficits better than traditional diagnoses.

Authors:  Faith M Hanlon; Ronald A Yeo; Nicholas A Shaff; Christopher J Wertz; Andrew B Dodd; Juan R Bustillo; Shannon F Stromberg; Denise S Lin; Swala Abrams; Jingyu Liu; Andrew R Mayer
Journal:  Schizophr Res       Date:  2019-01-31       Impact factor: 4.939

2.  Assessment of Neurocognitive Functions in 7-Year-Old Children at Familial High Risk for Schizophrenia or Bipolar Disorder: The Danish High Risk and Resilience Study VIA 7.

Authors:  Nicoline Hemager; Kerstin J Plessen; Anne Thorup; Camilla Christiani; Ditte Ellersgaard; Katrine Søborg Spang; Birgitte Klee Burton; Maja Gregersen; Anne Søndergaard; Aja Neergaard Greve; Ditte Lou Gantriis; Gry Poulsen; Larry J Seidman; Ole Mors; Merete Nordentoft; Jens Richardt Møllegaard Jepsen
Journal:  JAMA Psychiatry       Date:  2018-08-01       Impact factor: 21.596

3.  Neurocognitive subtypes in patients with bipolar disorder and their unaffected siblings.

Authors:  M Russo; T E Van Rheenen; M Shanahan; K Mahon; M M Perez-Rodriguez; A Cuesta-Diaz; E Larsen; A K Malhotra; K E Burdick
Journal:  Psychol Med       Date:  2017-06-07       Impact factor: 7.723

4.  Latent Profiles of Cognitive Control, Episodic Memory, and Visual Perception Across Psychiatric Disorders Reveal a Dimensional Structure.

Authors:  Jason Smucny; Ana-Maria Iosif; Nicholas R Eaton; Tyler A Lesh; J Daniel Ragland; Deanna M Barch; James M Gold; Milton E Strauss; Angus W MacDonald; Steven M Silverstein; Cameron S Carter
Journal:  Schizophr Bull       Date:  2020-01-04       Impact factor: 9.306

5.  Higher order theory of mind in patients with bipolar disorder and schizophrenia/schizoaffective disorder.

Authors:  Guillem Navarra-Ventura; Muriel Vicent-Gil; Maria Serra-Blasco; Jesús Cobo; Sol Fernández-Gonzalo; Ximena Goldberg; Mercè Jodar; Josep Maria Crosas; Diego Palao; Guillermo Lahera; Eduard Vieta; Narcís Cardoner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-05-04       Impact factor: 5.270

6.  Heterogeneity of social cognitive and language functions in children at familial high-risk of severe mental illness; The Danish High Risk and Resilience Study VIA 7.

Authors:  Merete Nordentoft; Jens Richardt Møllegaard Jepsen; Camilla Jerlang Christiani; Nicoline Hemager; Ditte Ellersgaard; Anne A E Thorup; Katrine Søborg Spang; Birgitte Klee Burton; Maja Gregersen; Anne Søndergaard; Aja Greve; Ditte Lou Gantriis; Ole Mors; Kerstin J Plessen
Journal:  Eur Child Adolesc Psychiatry       Date:  2021-02-09       Impact factor: 4.785

Review 7.  Cognitive Impairment in Bipolar Disorder: Treatment and Prevention Strategies.

Authors:  Brisa Solé; Esther Jiménez; Carla Torrent; Maria Reinares; Caterina Del Mar Bonnin; Imma Torres; Cristina Varo; Iria Grande; Elia Valls; Estela Salagre; Jose Sanchez-Moreno; Anabel Martinez-Aran; André F Carvalho; Eduard Vieta
Journal:  Int J Neuropsychopharmacol       Date:  2017-08-01       Impact factor: 5.176

8.  Sex-specific association of a common GNAS polymorphism with self-reported cognitive empathy in healthy volunteers.

Authors:  Franz Korbinian Huetter; Peter Alexander Horn; Winfried Siffert
Journal:  PLoS One       Date:  2018-10-26       Impact factor: 3.240

9.  Theory of mind in remitted bipolar disorder: Interpersonal accuracy in recognition of dynamic nonverbal signals.

Authors:  Usue Espinós; Enrique G Fernández-Abascal; Mercedes Ovejero
Journal:  PLoS One       Date:  2019-09-11       Impact factor: 3.240

10.  Decoding and reasoning mental states in major depression and social anxiety disorder.

Authors:  Gheysar Maleki; Abbas Zabihzadeh; Mara J Richman; Zsolt Demetrovics; Fatemeh Mohammadnejad
Journal:  BMC Psychiatry       Date:  2020-09-24       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.